59 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Oct 2030
Next term end
32
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2033 · High confidence
Also notable
Ends Feb 2035 · High confidence
Also notable
Ends Jun 2036 · Medium confidence
Also notable
Ends May 2032 · High confidence
Also notable
Ends Jun 2036 · High confidence
Also notable
Ends May 2041 · High confidence
Also notable
Ends Nov 2038 · High confidence
Also notable
Ends Feb 2035 · High confidence
SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS
US 10,533,013
Cited by 16 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Salts and Solid Form of a BTK Inhibitor
US 10,092,569
Cited by 17 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Tyrosine Kinase Inhibitors
US 9,688,676
Cited by 17 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
Tyrosine Kinase Inhibitors
US 8,962,831
The most cited patent in this portfolio, cited by 64 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2032.
Heterocycle Comprising Tyrosine Kinase Inhibitors
US 11,155,544
Cited by 9 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2036.
Crystalline Forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US 11,814,390
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2041.
Immunoproteasome Inhibitors
US 11,225,493
Granted 2022. Computed term ends 2038.
Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors
US 11,078,199
A family of 8 related applications built on the 2021 grant. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 25 to 28, 2027 · next Jan 25
- 1 fee due Apr 29, 2027The maintenance fee for Salts and Solid Form of a BTK Inhibitor (US 10,456,403) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
- 4 fees due May 14 to 28, 2027 · next May 14
- 4 fees due Jul 14 to 21, 2027 · next Jul 14
- 1 fee due Aug 23, 2027The maintenance fee for SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS (US 9,266,895) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS) (US 11,969,418) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
- 1 fee due Nov 19, 2027The maintenance fee for LMP7 Inhibitors (US 10,654,843) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 22, 2026
What they patent
The largest of its 32 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,426,428 | Egfr Kinase Knockdown via Electrophilically Enhanced Inhibitors In force · High confidence | In force | High confidence | |
| US 8,962,831 | Tyrosine Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,187,487 | Azaindole Derivatives as Tyrosine Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,376,438 | Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,673,925 | Tyrosine Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,759,358 | Tyrosine Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,946,241 | Tyrosine Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,962,635 | Tyrosine Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,090,621 | Tyrosine Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,957,080 | Tyrosine Kinase Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 59: 32 applications pending · 21 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.